*AAKASHAYA
PATRA EXCLUSIVE STOCK FOR INVESTMENT:* 12.04.2020
JAGSONPAL PHARMACEUTICALS LTD
CMP 24.5 ENTRY 20 TO 22
STOPLOSS 16 TARGET 50++ TIME: 24 MONTHS
Incorporated in 1964, Delhi based Jagsonpal
Pharmaceuticals Limited develops and manufactures active pharmaceutical
ingredients (APIs) and formulations. Its APIs include allylestrenol,
dextropropoxyphene HCL, dextropropoxyphene napsylate, disulfiram, thiopental
sodium, thiopental acid, tolnaftate, and sildenafil citrate, as well as
metformin HCL, BP, USP, and EP. The company also offers formulations for
various therapeutic categories, such as anabolic steroids, analgesics,
anesthetics, anti-allergic, anti-asthamatics,anti-cholinergic agents,
anti-convulsants, anti-diabetics, anti-diarrhoeals, anti-emetics,
anti-epileptics, antifungal agents, anti-gout agents, anti-inflammatory agents,
anti-malarials, anti-nauseants, anti-protozoals,anti-pyretic, anti-rheumatic
drugs, anti-spasmodic agents, and anti-septic agents. The company sells its products
under the Lycored, Maintane, Metadec, Metabol, Doxypal DR, Parvon, and Indocap
SR brand names through agents worldwide.
It has an equity base of just Rs.13.10 crore that is
supported by huge reserve of around Rs.95.41 crore.The promoters hold 70.34%
while the investing public holds 29.66% stake in the company. Promoters regularly
buy shares from open market since last long time which is positive sign. JPL's
share book value works out to Rs.37. Its P/BV ratio stands at just 0.66x.Company
has reported strong numbers for Q3FY20. During Q3FY20, JPL posted 31.03% higher
PAT of Rs.2.28crore on higher sales of Rs.42.01crore fetching an EPS of
Rs.0.87. During 9MFY20, it reported 49% higher PAT of Rs.6.32crore on sales of
Rs.129.05crore fetching an EPS of Rs.2.41. At CMP stock is trading at PE ratio
of 7x. It has paid 5% dividend for FY19. Company is manufacturing
anti-malarials medicine which is highly demandable drug at current time.
Comments
Post a Comment